1. Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge
- Author
-
G. Barrie Kitto, D. Mark Estes, Kate M. Johnson, Omar I Qazi, Arpaporn Deeraksa, Barbara M. Judy, Gregory C. Whitlock, Katherine Taylor, Katie L. Propst, Alfredo G. Torres, Katherine A. Brown, Angie J. Duffy, and Steven W. Dow
- Subjects
Bordetella pertussis ,Melioidosis ,BrkA autotransporter ,Immunology ,Pharmaceutical Science ,Live mucosal vaccine ,law.invention ,Microbiology ,03 medical and health sciences ,Burkholderia mallei ,Immunity ,law ,Drug Discovery ,medicine ,BPZE1 ,030304 developmental biology ,0303 health sciences ,biology ,030306 microbiology ,Glanders ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,biology.organism_classification ,medicine.disease ,Virology ,3. Good health ,Infectious Diseases ,Burkholderia ,Recombinant DNA ,Autotransporter domain ,bacteria ,Enterovirus 71 - Abstract
Burkholderia mallei and B. pseudomallei are Gram-negative pathogenic bacteria, responsible for the diseases glanders and melioidosis, respectively. Furthermore, there is currently no vaccine available against these Burkholderia species. In this study, we aimed to identify protective proteins against these pathogens. Immunization with recombinant B. mallei Hcp1 (type VI secreted/structural protein), BimA (autotransporter protein), BopA (type III secreted protein), and B. pseudomallei LolC (ABC transporter protein) generated significant protection against lethal inhaled B. mallei ATCC23344 and B. pseudomallei 1026b challenge. Immunization with BopA elicited the greatest protective activity, resulting in 100% and 60% survival against B. mallei and B. pseudomallei challenge, respectively. Moreover, sera from recovered mice demonstrated reactivity with the recombinant proteins. Dendritic cells stimulated with each of the different recombinant proteins showed distinct cytokine patterns. In addition, T cells from immunized mice produced IFN-γ following in vitro re-stimulation. These results indicated therefore that it was possible to elicit cross-protective immunity against both B. mallei and B. pseudomallei by vaccinating animals with one or more novel recombinant proteins identified in B. mallei.
- Published
- 2010
- Full Text
- View/download PDF